EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer
August 07, 2022 04:10 ET
|
EQRx, Inc.
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in...
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
July 28, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
June 14, 2022 07:00 ET
|
Eqrx, Inc.
Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated...
EQRx to Participate at Upcoming Investor Conferences
May 31, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
May 26, 2022 17:00 ET
|
Eqrx, Inc.
In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV...
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
May 13, 2022 07:00 ET
|
Eqrx, Inc.
New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3...
EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
April 29, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
April 27, 2022 10:30 ET
|
Eqrx, Inc.
First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung...
EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
March 23, 2022 07:00 ET
|
Eqrx, Inc.
First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDAContinue expanding the...
EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022
March 09, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...